US-Listed In Vitro & In Vivo Diagnostic Substances — Operating Income Percentiles, FY 2020

Population: 23 US-listed companies (SIC 2835), fiscal year 2020; fiscal year ends 2020-06-30 to 2021-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile	$-78.8M
25th percentile	$-25.5M
Median	$-7.5M
75th percentile	$33.0M
90th percentile	$573.3M
Mean	$101.0M
Minimum	$-289.7M
Maximum	$1.1B

Methodology & sources
Operating Income as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2020 = fiscal years ending 2020-06-01 to 2021-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-02.

Evidence samples

Latest Operating Income percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/operating-income/2020